For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Vyndamax and Tafamidis meglumine represents a genuine breakthrough . These innovative therapies preserve the transthyretin protein, preventing its damaging build-up and alleviating the sev